ONVO
vs
S&P 500
ONVO
S&P 500
Over the past 12 months, ONVO has underperformed S&P 500, delivering a return of -62% compared to the S&P 500's +13% growth.
Stocks Performance
ONVO vs S&P 500
Performance Gap
ONVO vs S&P 500
Performance By Year
ONVO vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Organovo Holdings Inc
Glance View
Organovo Holdings, Inc. engages in the development of bioprinted human tissues that emulate human biology and disease. The company is headquartered in San Diego, California and currently employs 7 full-time employees. The company went IPO on 2013-08-02. The firm is focused on building high fidelity, three-dimensional (3D) tissues that recapitulate key aspects of human disease. The firm is targeting the intestine and has ongoing 3D tissue developments in Ulcerative colitis (UC) and Crohn's disease (CD). The firm uses its platform technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. NovoGen Bioprinters can dispense pure hydrogel formulations and also serve as important components of company's tissue prototyping and manufacturing platform. The firm also intends to use its bioprinting platform as well as 3D technologies to treat its target diseases.